

Behar-Cohen Francine

Current position: Professor of Medicine, Ophthalmology, University Paris cite, surgical and medical retina specialist at Cochin hospital AP-HP and at Foch Hospital Director of the team Physopathology of ocular diseases : therapeutic innovations at the Centre de Recherche des Cordeliers, Paris France
Founder of Eyevensys SAS France and of co-founder of Early Sight Switzerland

Past positions

- 2017-2013: Chairman Jules Gonin Eye Hospital and Fondation Asile des Aveugles Lausanne
- 2007-May 2013: Full Professor in Ophthalmology at Hotel- Dieu Hospital, Université Paris Descartes.
- 2001-2006: Inserm permanent researcher position CR1 Inserm U450, Head of laboratory
- 2003- present: Head of Inserm laborto
- 2001-2003: Laureate of an Inserm Avenir Team
- 1997-2000 : Associate Professor (Chef de Clinique) Department of Ophthalmology of Hotel Dieu hospital Paris
- 1998: PhD, Life Sciences, Paris Descartes University, France
- 1988-1992: Residency in Ophthalmology, Paris, France
- 1995: MD, University Paris Descartes Medical School, France
- 1989: Master in cell Biology, Paris Descartes University

Scientific Expertise

- Ophthalmology teaching (medical and scientific students and professionals)
- Member of the scientific Inserm evaluation committee in neurosciences (CSS 1), 2007- 2012
- Expert for government institutions : President of group of work on LED at the ANSES (2009-2011), President of group of work on 3D technologies (2010-2015), president of the GT-LED2 (2015-present). Member of the group of work on virtual reality (2018-2021)
- Member of the comité d'expert scientifique at the ANSES (french agency for the security of environment) (2010-2012)
- Member of the scientific council of ANSES (2021-present)
- Member of the Scenihp (2011-2012) (EU committee for the evaluation of security of emerging technologies).
- Member of the Scientific Council of the Fondation pour la Recherche Médicale (2011-2015)
- Member of the Fédération des Aveugles et Handicapés Visuels (2011-present)
- Editorial board member of: Progress in Retinal and Eye Research (IF:11), Molecular Vision, Translational Visual Science and technology, Ophthalmologica, Journal of Ocular Pharmacology.
- Scientific committee of International Society of Ocular Pharmacology and Therapeutic.
- Member of the Bayer Vision Academy (2018-present)
- Member of the Bayer Global International Award scientific committee (2018-present)

VALORIZATION

- Inventor of more than 35 family patents
- Founder of Optis France in 1999, now Eyegate Pharma Int (Boston, USA)
- Founder of Eyevensys SAS in 2008
- Founder of EarlySight Switerland in 2016

President of the Pour la Vision patient Association [Pour la vision | Association CRO<https://www.pourlavision.org>]

Distinctions, Prizes

Grand prix Inserm pour l'innovation (2021), Marie Paul Burrus Fondation pour la Recherche Médicale Prize (2020), Euretina Award Lecture, (2017), Ophthalmology Dalloz Prize, Institut de France (2005), Oséo-Anvar émergence (2006) , Oséo-Anvar pour la Création d'entreprise (2007), International Uveitis Study Group for the best paper of the year (2007), Fondation de l'Avenir Prize (2008), Chevalier de la Légion d'Honneur (2010)

Author of more than 500 original publications, 18 book chapters, h index 51 on Clarivate, 61 on Goggle Scholar.

Main contributions in the field

F. Behar-Cohen has developed several methods to deliver drugs into the eye:

- Transscleral iontophoresis from bench to bedside (1997)
- First application of polymeric nanoparticles for posterior segment delivery (1999)
- Suprachoroidal delivery (2001)
- Ciliary muscle and suprachoroidal electrotransfer of plasmids developed up to first clinical trial in humans.

She has introduced the use of mineralocorticoid antagonists for the treatment of retinal diseases.